When Per Falk, Ferring’s chief science officer, assumes the additional responsibility of becoming president of the executive committee on January 1 next year, he will be the envy of many big pharma leaders. 5 November 2018
Michel Pettigrew, the most senior officer at privately-held drugmaker Ferring, is to retire at the end of the year, the Switzerland-based company has announced. 31 October 2018
Jesper Brandgaard (pictured above) is to retire after 20 years with Danish pharma major Novo Nordisk, vacating the role of executive vice president, Biopharm and Legal Affairs. 15 October 2018
Incoming Pfizer chief executive Albert Bourla is to stamp his mark firmly on the company’s leadership, as the firm announced a new executive team ready to clock on from the commencement of his tenure next year. 10 October 2018
Ireland-headquartered generic and OTC drugmaker Perrigo, which recently said it was restructuring into two separate units, has announced the appointment of Murray Kessler as president, chief executive and member of the board of directors, effective immediately. 10 October 2018
Ian Read’s eight-year stint as chief executive of the world’s biggest pharma company will come to an end in three months time, when he will be replaced by current chief operating officer (COO), Albert Bourla. 1 October 2018
German pharma major Bayer has appointed Sebastian Guth as president of Pharmaceuticals, Americas Region, comprising the USA, Canada, Central and Latin America, effective December 1, 2018. 28 September 2018
Current Boehringer Ingelheim chief medical officer Christopher Corsico is to move to British drugmaker GlaxoSmithKline at the end of the year. 20 September 2018
Canada’s Zymeworks, a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today named Anthony (Tony) Polverino, executive vice president of early development and chief scientific officer. 19 September 2018
Sanofi today announced that it will change the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations in mature markets and across emerging markets. 13 September 2018
Boehringer Ingelheim today announced that Dr Christopher Corsico, senior vice president, corporate division Medicine and chief medical officer, will be leaving the German family-owned pharma major to pursue his career outside of the company effective December 31, 2018. 11 September 2018
Ironshore Pharmaceuticals, a wholly-owned subsidiary of Canada’s Highland Therapeutics, has appointed Scott Evangelista to the position of president and chief operating officer (COO). 7 September 2018
London-listed Arix Bioscience has announced a change to its executive team which will see current chief executive Joe Anderson moved to the role of chief investment officer. 4 September 2018
Switzerland-based Tillotts Pharma, part of the Japanese Zeria Group, has announced that Karima Boubekeur is joining the company to take on the newly-created role of global head of innovation. 3 September 2018
EMD Serono, the biopharmaceutical business of Merck KGaA in the USA and Canada, today announced that Rehan Verjee has been appointed president of EMD Serono and global head of innovative medicine franchises of Merck. 31 August 2018
Indianapolis, USA-based Eli Lilly has announced that Anne White is to become president of Lilly Oncology and senior vice president of Lilly, effective September 1, 2018. 31 August 2018
US pharma major Bristol-Myers Squibb yesterday announced that Christopher Boerner has been appointed executive vice president and chief commercial officer, effective immediately. 29 August 2018
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024